📊 ASRT Key Takeaways
Is Assertio Holdings, Inc. (ASRT) a Good Investment?
Assertio is a deeply unprofitable pharmaceutical company with severe operational challenges, generating substantial negative cash flow of -$28.2M while revenue declined 5% YoY. The company is burning cash at an unsustainable rate with only $10.2M in liquid assets against $39.1M in debt, creating critical solvency risk within 12-18 months without operational turnaround or capital infusion.
Assertio's fundamentals are weak: revenue is declining, margins are deeply negative, and the business is consuming cash rather than generating it. While near-term liquidity is acceptable and leverage is not extreme, the combination of operating losses, negative free cash flow, and poor returns on assets and equity points to deteriorating earnings quality and limited financial flexibility if performance does not improve.
Why Buy Assertio Holdings, Inc. Stock? ASRT Key Strengths
- Positive current ratio of 1.70x and quick ratio of 1.51x suggest adequate short-term liquidity position
- Moderate debt-to-equity ratio of 0.42x indicates leverage is not immediately excessive relative to equity base
- Maintains $267.0M in total assets providing some balance sheet cushion
- Current and quick ratios indicate adequate near-term liquidity
- Debt load appears manageable relative to equity
- Positive equity base provides some balance sheet support
ASRT Stock Risks: Assertio Holdings, Inc. Investment Risks
- Severe cash burn of -$28.2M annually with only $10.2M cash on hand creates critical runway crisis within months
- Negative net margin of -25.6% and operating margin of -18.1% indicate core business is fundamentally unprofitable
- Revenue contraction of 5% YoY combined with deteriorating profitability suggests loss of market share and operational momentum
- Net income deteriorated 40.7% YoY demonstrating worsening financial trajectory
- Negative free cash flow of -$28.2M with zero capital expenditure indicates operational losses, not growth investments
- Revenue declined 5.0% year over year, indicating weak top-line momentum
- Operating margin of -18.1% and net margin of -25.6% show severe profitability pressure
- Negative operating cash flow and free cash flow increase dependence on balance sheet resources
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Revenue stabilization or return to growth in pharma product portfolio
- Monthly cash burn rate and runway remaining before potential insolvency
- Operating margin improvement through cost reduction or pricing initiatives
- Changes in insider buying patterns which show 13 Form 4 filings but likely reflect option exercises rather than confidence
- Operating cash flow and free cash flow trend
- Revenue stabilization and operating margin improvement
Assertio Holdings, Inc. (ASRT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Assertio Holdings, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ASRT Profit Margin, ROE & Profitability Analysis
ASRT vs Healthcare Sector: How Assertio Holdings, Inc. Compares
How Assertio Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Assertio Holdings, Inc. Stock Overvalued? ASRT Valuation Analysis 2026
Based on fundamental analysis, Assertio Holdings, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Assertio Holdings, Inc. Balance Sheet: ASRT Debt, Cash & Liquidity
ASRT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Assertio Holdings, Inc.'s revenue has grown significantly by 13% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.40 indicates the company is currently unprofitable.
ASRT Revenue Growth, EPS Growth & YoY Performance
ASRT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $29.2M | -$2.9M | $-0.03 |
| Q2 2025 | $29.2M | -$3.7M | $-0.04 |
| Q1 2025 | $26.5M | -$4.5M | $-0.05 |
| Q3 2024 | $29.2M | -$2.9M | $-0.03 |
| Q2 2024 | $31.1M | -$3.7M | $-0.04 |
| Q1 2024 | $32.4M | -$3.5M | $-0.05 |
| Q3 2023 | $34.2M | $4.2M | $0.08 |
| Q2 2023 | $35.1M | $5.0M | $0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Assertio Holdings, Inc. Dividends, Buybacks & Capital Allocation
ASRT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Assertio Holdings, Inc. (CIK: 0001808665)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASRT
What is the AI rating for ASRT?
Assertio Holdings, Inc. (ASRT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASRT's key strengths?
Claude: Positive current ratio of 1.70x and quick ratio of 1.51x suggest adequate short-term liquidity position. Moderate debt-to-equity ratio of 0.42x indicates leverage is not immediately excessive relative to equity base. ChatGPT: Current and quick ratios indicate adequate near-term liquidity. Debt load appears manageable relative to equity.
What are the risks of investing in ASRT?
Claude: Severe cash burn of -$28.2M annually with only $10.2M cash on hand creates critical runway crisis within months. Negative net margin of -25.6% and operating margin of -18.1% indicate core business is fundamentally unprofitable. ChatGPT: Revenue declined 5.0% year over year, indicating weak top-line momentum. Operating margin of -18.1% and net margin of -25.6% show severe profitability pressure.
What is ASRT's revenue and growth?
Assertio Holdings, Inc. reported revenue of $118.7M.
Does ASRT pay dividends?
Assertio Holdings, Inc. does not currently pay dividends.
Where can I find ASRT SEC filings?
Official SEC filings for Assertio Holdings, Inc. (CIK: 0001808665) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASRT's EPS?
Assertio Holdings, Inc. has a diluted EPS of $-4.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ASRT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Assertio Holdings, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ASRT stock overvalued or undervalued?
Valuation metrics for ASRT: ROE of -32.3% (sector avg: 15%), net margin of -25.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ASRT stock in 2026?
Our dual AI analysis gives Assertio Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASRT's free cash flow?
Assertio Holdings, Inc.'s operating cash flow is $-28.2M, with capital expenditures of $0.0. FCF margin is -23.7%.
How does ASRT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -25.6% (avg: 12%), ROE -32.3% (avg: 15%), current ratio 1.70 (avg: 2).